Search results for "Percutaneous"

showing 10 items of 471 documents

Influence of gender on delays and early mortality in ST-segment elevation myocardial infarction: Insight from the first French Metaregistry, 2005–201…

2018

International audience; Background - Women show greater mortality after acute myocardial infarction. We decided to investigate whether gender affects delays and impacts in-hospital mortality in a large population.Methods and results - We performed a patient-level analysis of 7 French MI registries from different regions from January 2005 to December 2012. All patients with acute STEMI were included within 12 h from symptom onset and a first medical contact with a mobile intensive care unit an emergency department of a hospital with percutaneous coronary intervention facility. Primary study outcomes were STEMI, patient and system, delays. Secondary outcome was in-hospital mortality. 16,733 p…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatment030204 cardiovascular system & hematologyCoronary AngiographyClinical researchSTEMIElectrocardiography03 medical and health sciencesSex Factors0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRisk FactorsGender issuesmedicineHumansST segmentRegistries030212 general & internal medicineMyocardial infarctionSex DistributionSurvival rateAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testbusiness.industryPercutaneous coronary interventionRetrospective cohort studyEmergency departmentMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPrognosismedicine.disease3. Good healthSurvival RateClinical researchEmergency medicineST Elevation Myocardial InfarctionFemale[SDV.IB]Life Sciences [q-bio]/BioengineeringCardiology and Cardiovascular MedicinebusinessElectrocardiographyFollow-Up StudiesInternational Journal of Cardiology
researchProduct

Outcomes of a routine invasive strategy in elderly patients with non-ST-segment elevation myocardial infarction from 2005 to 2014: results from the P…

2019

Background Elderly patients (≥75 years old) with non-ST-segment elevation myocardial infarction (NSTEMI) represent a large subgroup of all cases. They are rarely included in randomized trials because of comorbidities and concerns about complications. Furthermore, invasive treatments are used less frequently in this patient group. The aim of this study was to analyze trends in invasive procedures and outcomes in elderly patients with NSTEMI from 2005 to 2014. Patients and methods We analyzed 68 978 elderly patients with NSTEMI enrolled in the prospective, nationwide Polish Registry of Acute Coronary Syndromes from 2005 to 2014. Results Elderly patients accounted for 34.9% of all patients wit…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatment030204 cardiovascular system & hematologyCoronary AngiographyRisk Assessmentlaw.invention03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionSex FactorsRandomized controlled triallawPredictive Value of TestsRisk FactorsInternal medicinemedicineST segmentHumans030212 general & internal medicineMyocardial infarctionHospital MortalityRegistriesHealthcare DisparitiesNon-ST Elevated Myocardial InfarctionAgedbusiness.industryAge FactorsPercutaneous coronary interventionGeneral MedicineMiddle Agedmedicine.diseaseConfidence intervalStandardized mortality ratioTreatment OutcomePredictive value of testsRelative riskFemalePolandCardiology and Cardiovascular MedicinebusinessCoronary artery disease
researchProduct

Initial experience with the novel BioMime 60 mm-long sirolimus-eluting tapered stent system in long coronary lesions

2017

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentCoronary Artery Disease030204 cardiovascular system & hematologyCoronary AngiographyProsthesis Design03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineRisk FactorsmedicineHumansProspective Studies030212 general & internal medicineNon-ST Elevated Myocardial InfarctionAgedSirolimusbusiness.industryStentCardiovascular AgentsDrug-Eluting StentsMiddle AgedSurgeryTreatment OutcomeSirolimusFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugEuroIntervention
researchProduct

Reperfusion strategy in Europe: temporal trends in performance measures for reperfusion therapy in ST-elevation myocardial infarction

2010

Aims The rate and type of reperfusion, as well as time delays to reperfusion are directly associated with mortality and are established as performance measures (PMs) in the treatment of ST elevation myocardial infarction (STEMI). To date, little information exists about PMs for reperfusion in clinical practice in Europe and their temporal changes. Methods and results Using the Euro Heart Survey ACS-III data set (2 years of inclusions between 2006 and 2008, 138 centres in 21 countries), we selected patients with STEMI eligible for reperfusion therapy. Recorded variables corresponded to the CARDS data set. The rate and type of reperfusion, as well as door to needle and door to artery times we…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMyocardial InfarctionHemorrhageMyocardial ReperfusionReperfusion therapyFibrinolytic AgentsRecurrenceAngioplastyInternal medicinemedicineHumansMyocardial infarctionAngioplasty Balloon CoronaryStrokebusiness.industryST elevationPercutaneous coronary interventionMiddle Agedmedicine.diseaseEuropeHospitalizationStrokeTreatment OutcomeConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessFibrinolytic agentEuropean Heart Journal
researchProduct

Comparison of Ivabradine Versus Metoprolol in Early Phases of Reperfused Anterior Myocardial Infarction With Impaired Left Ventricular Function: Prel…

2009

BACKGROUND: beta-blockers in ST-segment elevation myocardial infarction (STEMI) are indicated for patients without a contraindication, particularly in patients with high heart rates (HR) or blood pressures. Epidemiological studies have shown that elevated HR represents a risk factor for cardiovascular morbidity. The study investigates the feasibility, tolerability, and the effects after 30 days of follow-up of ivabradine (IVA) versus metoprolol (METO) in early phases of anterior STEMI reperfused by percutaneous coronary intervention (PCI). METHODS AND RESULTS: Patients with a first anterior STEMI, Killip class I-II, an acceptable echocardiographic window, and admitted within 4hours of the o…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMyocardial InfarctionMyocardial Reperfusion InjuryPilot ProjectsVentricular Dysfunction LeftDouble-Blind MethodInternal medicineejection fraction end systole volume ivabradinemedicineHumansIvabradinecardiovascular diseasesMyocardial infarctionAgedMetoprololKillip classEjection fractionbusiness.industryPercutaneous coronary interventionBenzazepinesMiddle Agedmedicine.diseasesurgical procedures operativeConventional PCICardiologyMyocardial infarction complicationsFemaleCardiology and Cardiovascular MedicinebusinessIvabradineFollow-Up StudiesMetoprololmedicine.drugJournal of Cardiac Failure
researchProduct

Prognostic value of ST-segment resolution after rescue percutaneous coronary intervention. Data from the RICO survey

2008

Objectives: The goal of the present study was to test the impact of ST segment resolution (STR) after rescue percutaneous coronary intervention (PCI) on the short-term prognosis. Background: The prognostic value of STR after rescue PCI for acute ST elevation myocardial infarction (STEMI) remains undetermined. Methods: From the French regional database, we analyzed 168 consecutive patients with STEMI and failed lysis, defined by <50 percent STR, who underwent rescue PCI. Patients were classified into two groups according to the degree of STR from the maximal ST-elevation measured on the single worst ECG lead before lysis and after rescue PCI: the without STR group (<50% STR) vs. the with STR…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMyocardial InfarctionRisk AssessmentElectrocardiographyCoronary CirculationInternal medicineOdds RatiomedicineHumansST segmentThrombolytic TherapyRadiology Nuclear Medicine and imagingProspective StudiesRegistriesTreatment Failurecardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryProspective cohort studyAgedIntra-Aortic Balloon Pumpingmedicine.diagnostic_testbusiness.industryPercutaneous coronary interventionGeneral MedicineThrombolysisMiddle AgedPrognosismedicine.diseaseeye diseasesSurgeryTreatment OutcomeCardiovascular DiseasesHealth Care SurveysConventional PCICardiologyFemaleStentsFranceCardiology and Cardiovascular MedicinebusinessElectrocardiographyTIMICatheterization and Cardiovascular Interventions
researchProduct

Real world safety and efficacy of the Janus Tacrolimus-Eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Elutin…

2009

Objectives: We sought to evaluate the safety and performance of the Janus Tacrolimus-Eluting stent (TES) in an unselected population of patients, without application of restrictive clinical or angiographic criteria. Background: Continued attention to the safety, efficacy, and deliverability of first-generation drug eluting stents has led to the development of new antiproliferative agents with alternative stent platforms and different drug carrier vehicles. Methods: The TEST (Tacrolimus Eluting STent) registry is a prospective, nonrandomized single-center registry in which 140 consecutive patients who underwent single- or multi-vessel percutaneous coronary intervention between February 2005 …

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPopulationMyocardial InfarctionRestenosiKaplan-Meier EstimateCoronary AngiographyProsthesis DesignRisk AssessmentTacrolimusCoronary RestenosisRestenosismedicineHumansRadiology Nuclear Medicine and imagingMyocardial infarctionProspective StudiesRegistriesAngioplasty Balloon CoronaryeducationAgededucation.field_of_studybusiness.industryCoronary StenosisStentPercutaneous coronary interventionTacrolimus eluting stent.Cardiovascular AgentsDrug-Eluting StentsGeneral MedicineMiddle Agedmedicine.diseaseTacrolimusSurgeryTreatment OutcomeAntiproliferative AgentsFemaleRadiologySafetyCardiology and Cardiovascular MedicinebusinessMaceCatheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventions
researchProduct

Feasibility of Implanting 50-60 mm-Tapered Drug Eluting Stents in Chronic Total Occlusions.

2018

Abstract Background Percutaneous coronary intervention (PCI) of chronic total occlusions (CTO) usually involves multiple overlapping stents implantation to cover long coronary segments. A higher rate of restenosis has been described with stent overlapping. Recently, new long tapered stents emerged as a potential tool for treating long coronary lesions. Feasibility of using these new devices for the CTO PCI has not been described. The aim of this work was to describe our initial experience with 50 and 60 mm-long tapered sirolimus-eluting stents (SES) in CTO PCI. Methods We included 54 consecutive patients who underwent a CTO PCI and in whom an attempt to implant a 50 or 60 mm-long tapered SE…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentTarget vessel030204 cardiovascular system & hematologyProsthesis DesignCoronary Restenosis03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionRestenosismedicineHumanscardiovascular diseases030212 general & internal medicineVascular PatencyAgedRetrospective StudiesSirolimusbusiness.industryPercutaneous coronary interventionStentCardiovascular AgentsDrug-Eluting StentsGeneral MedicineMiddle Agedmedicine.diseaseSurgerysurgical procedures operativeTreatment OutcomeCoronary OcclusionConventional PCIChronic DiseaseFeasibility StudiesFemaleImplantCardiology and Cardiovascular MedicinebusinessCardiovascular revascularization medicine : including molecular interventions
researchProduct

Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year fo…

2017

Objectives to compare the 1-year outcome between bioresorbable vascular scaffold (BVS), everolimus-eluting stent (EES), and drug-eluting balloon (DEB) for in-stent restenosis (ISR) treatment. Background BVS has been proposed as alternative for ISR treatment. To date a direct comparison between BVS and DES or DEB for ISR treatment is lacking. Methods We retrospectively analyzed all ISR lesions treated with BVS, DEB, and EES from January 2012 to December 2014. A total of 548 lesions (498 patients) were included. By applying two propensity-score matching, 93 lesions treated with BVS were compared with 93 lesions treated with DEB, and 100 lesions treated with BVS were compared to 100 lesions tr…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentUrology030204 cardiovascular system & hematologyProsthesis DesignBalloonRisk AssessmentCardiac CathetersCoronary Restenosis03 medical and health sciences0302 clinical medicineCoated Materials BiocompatibleRestenosisRisk FactorsAbsorbable ImplantsmedicineHumansRadiology Nuclear Medicine and imagingEverolimus030212 general & internal medicineAngioplasty Balloon CoronaryPropensity ScoreAgedRetrospective StudiesBioresorbable vascular scaffoldin stent restenosibusiness.industryIncidence (epidemiology)percutaneous coronary interventionStentPercutaneous coronary interventionCardiovascular AgentsDrug-Eluting StentsGeneral MedicineMiddle Agedmedicine.diseaseTreatment OutcomeItalyDrug-eluting stentPropensity score matchingFemalebioresorbable vascular scaffolddrug eluting balloonCardiology and Cardiovascular Medicinebusinessdrug eluting stent
researchProduct

Prognostic Value of Microvascular Obstruction and Infarct Size, as Measured by CMR in STEMI Patients

2014

The aim of this study was to evaluate the value of microvascular obstruction (MO) and infarct size as a percentage of left ventricular mass (15%LV), as measured by contrast-enhanced cardiac magnetic resonance, in predicting major cardiovascular adverse events (MACE) at 2 years in patients with ST-segment elevation myocardial infarction reperfused by primary percutaneous coronary intervention. Individual data from 1,025 patients were entered into the pooled analysis. MO was associated with the occurrence of MACE, defined as a composite of cardiac death, congestive heart failure, and myocardial re-infarction (adjusted hazard ratio: 3.74; 95% confidence interval: 2.21 to 6.34). IS% LV >= 25% w…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentmicrovascular obstructionHeart VentriclesMyocardial Infarction[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineRisk Assessmentcardiac magnetic resonance[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicinePercutaneous Coronary InterventionPredictive Value of TestsRecurrenceRisk FactorsInternal medicineCoronary CirculationMedicineinfarct sizeHumansRadiology Nuclear Medicine and imagingMyocardial infarctioncardiovascular diseasesAdverse effectComputingMilieux_MISCELLANEOUSAgedHeart Failurebusiness.industryMicrocirculationMyocardiumHazard ratioPercutaneous coronary interventionMiddle Agedmedicine.diseaseMagnetic Resonance ImagingConfidence intervalTreatment OutcomeRadiology Nuclear Medicine and imagingHeart failureNo reflow phenomenonCardiologyNo-Reflow PhenomenonFemaleprognosisCardiology and Cardiovascular MedicinebusinessMaceJACC. Cardiovascular imaging
researchProduct